Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416758 | 0.86 | CTSK (0.40) | METAP2CTSKCTSSMMP1MMP13 | |
| SCHEMBL3806162 | 0.80 | METAP2 (0.44) | METAP2CTSKAAK1METAP1 | |
| SCHEMBL240252 | 0.80 | METAP2 (0.44) | METAP2CTSKAAK1METAP1 | |
| SCHEMBL702585 | 0.80 | METAP2 (0.44) | METAP2CTSKAAK1METAP1 | |
| SCHEMBL702586 | 0.80 | METAP2 (0.44) | METAP2CTSKAAK1METAP1 | |
| SCHEMBL418389 | 0.80 | MMP1 (0.38) | MMP1AAK1TSHR | |
| Hydrochloric Acid SCHEMBL15619093 | 0.79 | MMP1 (0.38) | MMP1AAK1TSHR | |
| Hydrochloric Acid SCHEMBL15618898 | 0.79 | MMP1 (0.38) | MMP1AAK1TSHR | |
| Hydrochloric Acid SCHEMBL15618895 | 0.79 | MMP1 (0.38) | MMP1AAK1TSHR | |
| Hydrochloric Acid SCHEMBL240251 | 0.79 | METAP2 (0.43) | METAP2CTSKAAK1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| EP-2368877-B1 | Peptidomimetic protease inhibitors and intermediates for their preparation As treatment for HCV infection | VERTEX PHARMA (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100324059-A1 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324059-A1 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| EP-1878720-A1 | Process for preparing chiral bicycloprolinates as intermediates for the preparation of peptidomimetic protease inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294763-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PREP, PEPD | METAP2 230/4885CTSK 86/4885CTSS 15/4885 |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | METAP2 230/4885CTSK 86/4885CTSS 15/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | METAP2 230/4885CTSK 86/4885CTSS 15/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | METAP2 172/4885CTSK 46/4885CTSS 8/4885 |
| US-20100324059-A1 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV | HAVCR2, LIPC, CPT1A | METAP2 404/4885CTSK 490/4885CTSS 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.